Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MATIS trial of ruxolitinib or fostamatinib plus best supportive treatment for COVID-19 pneumonia
2020-001750-22Phase 2Unknown
- Sponsor
- Joint Research Compliance Office
- Start
- Jul 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of ruxolitinib and fostamatinib in coronavirus pneumonia (3 arms), sponsored by Joint Research Compliance Office. Primary endpoint: Progression from mild to severe COVID-19 pneumonia within 14 days. Status: unknown.
02
Drugs
ruxolitinibfostamatinib
03
Conditions
coronavirus pneumonia
Beyond the preview
Go deeper on 2020-001750-22.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2020-001750-22.